Abstract

Cancer, as the most challenging part in the human disease history, has always been one of the main threats to human life and health. The high mortality of cancer is largely due to the complexity of cancer and the significant differences in clinical outcomes. Therefore, it will be significant to improve accuracy of cancer survival prediction, which has become one of the main fields of cancer research. Many calculation models for cancer survival prediction have been proposed at present, but most of them generate prediction models only by using single genomic data or clinical data. Multiple genomic data and clinical data have not been integrated yet to take a comprehensive consideration of cancers and predict their survival. In order to effectively integrate multiple genomic data (including genetic expression, copy number alteration, DNA methylation and exon expression) and clinical data and apply them to predictive studies on cancer survival, similar network fusion algorithm (SNF) was proposed in this paper to integrate multiple genomic data and clinical data so as to generate sample similarity matrix, min-redundancy and max-relevance algorithm (mRMR) was used to conduct feature selection of multiple genomic data and clinical data of cancer samples and generate sample feature matrix, and finally two matrixes were used for semi-supervised training through graph convolutional network (GCN) so as to obtain a cancer survival prediction method integrating multiple genomic data and clinical data based on graph convolutional network (GCGCN). Performance indexes of GCGCN model indicate that both multiple genomic data and clinical data play significant roles in the accurate survival time prediction of cancer patients. It is compared with existing survival prediction methods, and results show that cancer survival prediction method GCGCN which integrates multiple genomic data and clinical data has obviously superior prediction effect than existing survival prediction methods. All study results in this paper have verified effectiveness and superiority of GCGCN in the aspect of cancer survival prediction.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.